Sionna Therapeutics shares plunge 91.18% after trial misses key endpoint
AI Summary- Pomerantz LLP is investigating Sionna Therapeutics and certain officers or directors.
- Sionna shares fell $46.54, or 91.18%, to $4.50 on August 10, 2026.
- Sionna said its PreciSION CF trial failed to meet its key activity endpoint.